Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc, is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher Scientific Inc., extending the current license to include intellectual property relating to a new class of higher-plex TMT® reagents currently in development. Such higher-plex technology represents the next phase in the evolution of isobaric tagging and will enable further advances in the efficiency and utility of mass spectrometric protein analyses.

Jeremy Haigh, Chief Executive Officer of Proteome Sciences plc, commented: “We are delighted to extend our successful and exclusive collaboration with Thermo Fisher Scientific through which TMT® has become the market leader and established standard for multiplex, quantitative proteomic experiments. The development of higher-plex TMT® reagents has been a long-standing objective for Proteome Sciences and we look forward to continuing our partnership with a recognised world leader in serving science and innovation.”